新型生物标志物改善小儿先天性心脏病手术后365天再入院预测
本研究评估了术前生物标志物水平与小儿先天性心脏病手术后365天再入院或死亡之间的关联。在145例接受先天性心脏病手术的儿童中,联合临床模型与新型生物标志物面板将预测再入院或死亡的c统计量从0.719提升至0.805,且改善显著(P=0.035)。
要点
- 联合新型生物标志物可提高小儿先心术后365天再入院或死亡的预测能力
- 临床模型单独c统计量为0.719,联合生物标志物后提升至0.805
- 术前和术后ST2水平与365天再入院或死亡独立相关
核心结论
- 新型生物标志物可能为评估小儿先天性心脏病手术后365天再入院或死亡的可能性增加预测价值。
- 调整临床和新型生物标志物后,术前和术后ST2仍与365天再入院或死亡相关。
研究设计与样本
- 前瞻性队列研究,纳入2010年至2014年在约翰霍普金斯医院接受先天性心脏病手术的18岁及以下儿童145例。
- 测量了新型生物标志物ST2、galectin-3、NT-proBNP和GFAP。
- 复合终点为出院后365天内非计划再入院或手术住院期间死亡或出院后365天内死亡。
- 评估了基于STS先天性心脏病手术数据库死亡风险模型协变量的临床模型,以及联合新型生物标志物面板的增强模型。
主要发现
- 39例(27%)患者在手术后365天内发生再入院或死亡。
- 临床模型单独c统计量为0.719(95%CI 0.63-0.81)。
- 临床模型联合对数转换的生物标志物将c统计量提高至0.805(95%CI 0.73-0.88)。
- 添加生物标志物对临床模型有显著改善(P=0.035)。
关键数值与推荐
- 临床模型单独c统计量:0.719(95%CI 0.63-0.81)。
- 临床模型联合生物标志物c统计量:0.805(95%CI 0.73-0.88)。
- 联合模型与临床模型比较P=0.035。
临床怎么用
- STS临床先天性死亡风险模型可用于识别再入院和出院后死亡风险较高的儿童,并可能为旨在减少这些不良事件的预防性护理干预提供信息。
- 新型生物标志物 panel 可能辅助临床模型进行风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to evaluate the association between preoperative biomarker levels and 365-day readmission or mortality after pediatric congenital heart surgery. METHODS: Children aged 18 years or younger undergoing congenital heart surgery (n = 145) at Johns Hopkins Hospital from 2010 to 2014 were enrolled in the prospective cohort. Novel biomarkers suppression of tumorgenicity 2, galectin-3, N-terminal prohormone brain natriuretic peptide, and glial fibrillary acidic protein were measured. The composite study endpoint was unplanned readmission within 365 days after discharge or mortality either in hospital during the surgical admission or within 365 days after discharge. A clinical model based on covariates used in The Society of Thoracic Surgeons Congenital Heart Surgery Database mortality risk model and an augmented model using the clinical model in conjunction with a novel biomarker panel were evaluated. RESULTS: Readmission or mortality within 365 days of surgery occurred among 39 pediatric patients (27%). The clinical model alone resulted in a c-statistic of 0.719 (95% confidence interval, 0.63 to 0.81). The clinical model in conjunction with the log-transformed biomarkers improved the c-statistic to 0.805 (95% confidence interval, 0.73 to 0.88). The addition of biomarkers resulted in a significant improvement to the clinical model alone (P value = 0.035). CONCLUSIONS: Novel biomarkers may add predictive value when assessing the likelihood of 365-day readmission or mortality after pediatric congenital heart surgery. After adjusting for clinical and novel biomarkers, preoperative and postoperative suppression of tumorgenicity 2 remained associated with 365-day readmission or mortality. Currently, The Society of Thoracic Surgeons clinical congenital mortality risk model can be applied to identify children with increased risk of repeat hospitalizations and postdischarge mortality and may inform preventative care interventions that aim to reduce these adverse events.
引用
- Parker DM, Everett AD, Stabler ME, et al. Novel Biomarkers Improve Prediction of 365-Day Readmission After Pediatric Congenital Heart Surgery. Ann Thorac Surg. 2019. PMID: 31323208. doi:10.1016/j.athoracsur.2019.05.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。